RRM1 Underexpression

CI-VAR-00004416Explore in graph →CIViC 1257

Curated evidence

Evidence by cancer (12 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–12 of 12 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma10
RRM1 Underexpression	(prognostic)	Prognostic	B	Supports Better Outcome	2	submitted	EID8024 Expression level of RRM1 was evaluated in 61 NSCLC samples with RT-qPCR. Low expression of RRM1 was associated with longer median survival time (13.9 versus 10.9 months, P = 0.039). However, RRM1 expr… (full text at CIViC) PMID 16980606 · Ceppi et al., 2006 · Open in CIViC	civic
RRM1 Underexpression	Gemcitabine	Predictive	B	Supports Sensitivity Response	4	accepted	EID5530 In this study, 229 tumors were analyzed for RRM1 expression. This resulted in 146 that were negative for RRM1 expression and 83 that were positive. These tumors were studied for a relationship between… (full text at CIViC) PMID 24647522 · Dong et al., 2014 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Pancreatic Neoplasm2
RRM1 Underexpression	Gemcitabine	Predictive	B	Supports Sensitivity Response	3	accepted	EID5506 There were 68 patients enrolled in this study, 28 of which were treated with gemcitabine. Of those 28, 14 patients had a low RRM1 expression and 14 had a high RRM1 expression. Only the patients with … (full text at CIViC) PMID 19543324 · Akita et al., 2009 · Open in CIViC	civic
RRM1 Underexpression	Gemcitabine	Predictive	B	Supports Sensitivity Response	3	accepted	EID5508 In this study, human pancreatic carcinoma cell line MiaPaCa2, which is a gemcitabine-sensitive cell line, was used for the establishment of chemoresistant cells MiaPaCa2-RG. Analysis for identifying g… (full text at CIViC) PMID 17131328 · Nakahira et al., 2007 · Open in CIViC	civic